Induced pluripotent stem cell-derived chimeric antigen receptor natural killer cells: Engineering innovations, translational hurdles and clinical prospects in immune therapy

Table 4 Bottleneck layers, engineering and mitigation strategies, and key validation metrics in the clinical translation of induced pluripotent stem cell-derived chimeric antigen receptor natural killer cells

Bottleneck layer	Core bottlenecks/key translational constraints	Representative engineering/mitigation strategies	Key validation metrics	Key considerations for translational interpretation
Product definition layer	Insufficient differentiation consistency, batch-to-batch variability, risk of genetic instability, and risk of residual undifferentiated iPSCs	Clonal screening, establishment of master cell banks, standardized differentiation workflows, control of residual iPSCs, and optimization of cryopreservation and thawing processes	NK-cell purity, CAR positivity rate, cell viability, differentiation yield, post-thaw function, karyotype, CNV, genomic stability, residual pluripotency markers, and sterility, mycoplasma, and endotoxin testing	Determines whether the product can be manufactured consistently, assessed for quality, and compared across batches
Effector execution layer	Insufficient target-cell recognition, inadequate cytotoxic function, target-antigen heterogeneity or antigen downregulation, and insufficient serial killing capacity	NK-adapted CAR structural optimization, optimization of the antigen-recognition domain and affinity, hnCD16-mediated ADCC enhancement, multi-target design, logic gating, and cytokine support	Antigen-dependent killing, cytotoxicity at different E:T ratios, CD107a degranulation, granzyme B and perforin expression, cytokine release, serial killing capacity, antigen-negative escape, and killing of non-target cells	Enhanced in vitro effector function alone cannot be equated with in vivo efficacy or clinical benefit
Tissue delivery layer, including TME adaptation	Insufficient homing to solid tumors, extravasation, and infiltration into the tumor parenchyma; local TME-mediated suppression; hypoxia/metabolic stress; and remodeling of the antigenic landscape	Chemokine receptor engineering, adaptation to stromal barriers, TGF-β resistance, adenosine/A2A-axis adaptation, hypoxia-resistant or metabolically adaptive designs, and local TME-responsive modules	Chemotactic migration ability, tumor-tissue infiltration ratio, tumor-to-peripheral-blood cell ratio, spatial distribution, local persistence duration, markers related to TGF-β, adenosine, and hypoxia, and in vivo tumor-growth inhibitory activity	Requires determination of whether the main limitation arises from tissue delivery, local suppressive pathways, or antigen escape
Host interaction layer	Allogeneic immune-mediated clearance, insufficient in vivo persistence, accelerated clearance after repeat dosing, immunogenicity, and risk of “missing-self” recognition	HLA-related engineering, B2M/CIITA editing, HLA-E/HLA-G expression, evasion of host NK-cell-mediated clearance, and in vivo persistence-enhancing modules	In vivo expansion and persistence, cellular exposure levels in peripheral blood and tissues, host T/NK-cell clearance responses, anti-product immune responses, changes in cellular exposure after repeat dosing, and long-term safety	Determines the effective exposure duration and feasibility of repeat dosing; immune-evasion benefits need to be balanced against safety risks
Translational implementation layer	Safety risks associated with multiplex engineering, inadequate potency assays, non-uniform release criteria, insufficient comparability after process changes, and uncertainties in regulatory pathways and costs	Potency assay systems, release criteria, comparability studies, safety switches, long-term safety monitoring, manufacturing cost control, and optimization of cold-chain and supply-chain logistics	Batch production success rate, release pass rate, potency consistency, vector copy number, gene-editing off-target risk, replication-competent virus detection, manufacturing cycle, cost per dose, and long-term AE/SAE monitoring	Determines whether an engineering strategy can become a cell product that is amenable to regulatory evaluation, manufacturable, and clinically deployable

iPSCs: Induced pluripotent stem cells; NK: Natural killer; CAR: Chimeric antigen receptor; CNV: Copy number variation; ADCC: Antibody-dependent cellular cytotoxicity; TME: Tumor microenvironment; TGF-β: Transforming growth factor-β; B2M: Beta-2 microglobulin; HLA: Human leukocyte antigen; AE: Adverse event; SAE: Serious adverse event.